Formycon Ag · XETR:FYB
Formycon — Investor Presentation (January 2025)
20 slides from Formycon's investor presentation, January 2025
Slide 1: Formycon AG – The Biosimilar Experts
Formycon AG The Biosimilar Experts January 2025
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Skillset and mindset are our key ingredients
Skillset and mindset are our key ingredients Pure Play Biosimilar 250 employees from more Combining high professional Formycon's pipeline Company – established 2012 than 30 different countries. expertise in biopharma- includes three approved in Munich, Germany. ceutical development with biosimilars,
Slide 4: We are acting along a clear mission
We are acting along a clear mission Biosimilars open up enormous opportunities Contributing to ease Improving the financial strains on the patient access to vital world’s healthcare systems medicines 4 Formycon FormyconAG AG– //The TheBiosimilar BiosimilarExperts Experts
Slide 5: Maximizing our assets along a clear path
Laser focus on pipeline execution and expansion Maximizing our assets along a clear path 2023 2024 Strong financial Important year Sustainable and operational to prepare the profitability with performance ground for the continuous pipeline next ignition growth stage 5 Formycon AG Formycon AG // The
Slide 6: Many important milestones achieved in 2024
Many important Milestones achieved in 2024 – further exciting News expected in the upcoming weeks Positive CHMP Approval of Approval of Approval of Positive CHMP Opinion Opinion for Stelara® Stelara® Biosimilar- Stelara® Biosimilar- Eylea® Biosimilar- for Eylea® Biosimilar- Biosimilar-Candidate Cand
Slide 7: Huge Biosimilar target opportunities
Huge Biosimilar target opportunities > 40 Blockbuster drugs with an expected global sales volume of more than 200 USD billion will lose their exclusivity in the coming years, creating huge opportunities for Biosimilars Year Number of blockbuster drugs losing exclusivity Cumulative global annual peak
Slide 8: The Biosimilar market develops very dynamically
The Biosimilar market develops very dynamically Global Biosimilar Sales 2016 – 2030 USD billion* 74.0 2015 – 2021 2021 – 2025 RoW CAGR 39% RoW CAGR 16% US CAGR 97% US CAGR 26% Europe CAGR 48% Europe CAGR 8% Biosimilars is the fastest growing segment ● ROW 32.9 in Pharma. The US market ● US ● EUROPE
Slide 9: Full value chain covered in successful hybrid model
Full value chain covered in successful hybrid model With our team of highly experienced scientists and regulatory affairs experts, Formycon covers a large part of the Biosimilar development value chain in-house. For the areas of manufacturing and commercialization, we rely on well trusted long-term
Slide 10: Biosimilar development – high probability of success
Biosimilar development – high probability of success The probability of success for a Biosimilar is continuously high over the course of development1. This is different for innovative drug developments: Here, on average, only one in twelve innovative drugs makes it from the preclinical stage to appr
Slide 11: Strong maturing and growing pipeline
Strong maturing and growing pipeline Diversified portfolio of commercial, late and mid stage programs with multiple catalysts over the next 12 – 18 months Lucentis® 50% Further approvals Ophthalmology $2.0bn US* ex-US MENA (Genentech Inc.) owned and launches 2022 Stelara® Fully Launches in US, Immun
Slide 12: Lucentis Biosimilar FYB201 – Strong Performance across the World
Lucentis® Biosimilar FYB201 – Strong Performance across the World FYB201/Ranibizumab is so far launched in 20 Countries UK Marketshare: >80%* US Marketshare: >40%* FYB201 launched Further potential *Volume-based · Source: IQVIA Monthly Data R3M (rolling 3-month) Cimerli® is a registered trademark of
Slide 13: FYB202 – Stelara Biosimilar ready to launch
FYB202 – Stelara® Biosimilar ready to launch Approved Targeted Reference Indications Formycon Income Position Psoriasis (Arthritis), Crohn’s Disease, Ulcerative Colitis ● Milestone payments related to the completion of clinical phases of Target Market 2023 about 25 million in H1 2023. Additional mil
Slide 14: FYB203 – Eylea Biosimilar approved in US and recommended for EU
FYB203 – Eylea® Biosimilar approved in US and recommended for EU Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc. AHZANTIVE® is a registered trademark of Klinge Biopharma GmbH Approved CHMP Targeted Reference Indications Formycon Income Position Neovascular AMD1, DME2, mCNV3, RVO4
Slide 15: FYB206 – Keytruda Biosimilar Candidate in the leading group
FYB206 – Keytruda® Biosimilar Candidate in the leading group Targeted Reference Indications Achievements and next important Milestones Immuno-oncology: Melanoma (black skin cancer), ● Important IP has been generated non-small cell Lung Cancer, classical Hodgkin’s Lymphoma ● Clinical Phase I trial “D
Slide 16: Outlook for 2025 – next operational and commercial milestones
Outlook for 2025 – the next operational and commercial milestones are coming soon Approval of Approval of Approval of Commercial Launch Approval of Stelara® Biosimilar Stelara® Biosimilar Eylea® Biosimilar of Stelara® Biosimilar Lucentis® Biosimilar FYB202/Otulfi® in FYB202/Otulfi® in Candidate FYB2
Slide 17: Solid financial performance as expected
Solid financial Performance as expected Guidance ● Revenue: Revenue EBITDA Adjusted EBITDA* Working Capital 2024 4Q 2024 expected in the range of € 20m 55 to 65 -25 to -15 -5 to +5 35 to 45 ● EBITDA: 4Q EBITDA expected to be € million € million € million € million “black zero” ● Adjusted EBITDA At e
Slide 18: Uplisted to Prime Standard, part of SDAX and TecDAX
Formycon – uplisted to Prime Standard and Part of the SDAX and the TecDAX − Market Segment: Frankfurt Stock Exchange Shareholder Structure Regulated Market (Prime Standard) 24.04 % Santo Holding (Deutschland) GmbH − Uplisted to Prime Standard on Nov. 12, 2024, 13.25 % Wpart GmbH, Wen.Co Invest GmbH,
Slide 19: Fully focused pure-play Biosimilar Company
Fully focused pure-play Biosimilar Company WE HAVE all ingredients to WE ACT in a highly WE CREATED WE ARE entering the next successfully develop and attractive market a strong Platform with stage of the Formycon commercialize a growing track record Growth Story pipeline 19 Formycon AG // The Biosim
Slide 20: Formycon AG
Formycon AG Formycon AG Fraunhoferstr. 15 82152 Planegg-Martinsried Germany + 49 89 864 667 100 info@formycon.com www.formycon.com 20 Formycon AG Formycon AG // The Biosimilar Experts